Acorda Therapeutics announced that it has entered into a long-term global supply agreement with Catalent to manufacture INBRIJA (levodopa inhalation powder) in Boston through 2030. The agreement includes the scale-up to the larger pharma grade spray-dryer at a PSD-7 scale, which will provide expanded capacity for the long-term world-wide manufacturing requirements of INBRIJA.
Under the new supply agreement Acorda is required to purchase $8.5M in INBRIJA supply in 2023 and $15.5M in 2024, reduced from $18M annually. Beginning in 2025, Acorda will pay a fixed capsule fee based on the amount of INBRIJA needed in the US and other markets. By 2026, an expansion in Catalent’s manufacturing capacity is expected to reduce per-capsule prices significantly.
In addition, Acorda will pay an $8M termination fee to Catalent in connection with the termination of the prior global supply agreement, payable in two installments in June and December 2023, and $1M in each of 2023 and 2024 for capital expenditures at the manufacturing plant to assist in the capacity expansion.